PFIZER LTD. - 500680 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed press release for appointment of Ms. Meenakshi Nevatia (DIN: 08235844) as an Additional Director and Managing Director of the Company for a period of 5 years with effect from April 3, 2023. Request you to take the same on record. PFIZER LTD. - 500680 - Announcement under Regulation 30 (LODR)-Change in Directorate
Intimation is hereby given that Mr. S. Sridhar, Managing Director, who had decided to take early retirement (which was communicated to you vide our letter dated August 10, 2022 - copy enclosed) has submitted his resignation with effect from March 31, 2023. The Company places on record its appreciation for the leadership, guidance and support provided by Mr. S. Sridhar during his tenure. Request you to take the same on record. PFIZER LTD. - 500680 - Announcement under Regulation 30 (LODR)-Change in Directorate
Pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby Inform you that the Board of Directors of the Company at their Meeting held today appointed Ms. Meenakshi Nevatia (DIN: 08235844) as an Additional Director and Managing Director of the Company for a period of 5 years with effect from April 3, 2023. The appointment of Ms. Nevatia will be subject to the approval of shareholders through Postal Ballot and Central Government. Additional details required to be disclosed pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular Nos. CIR/CFD/CMD/412015 dated September 9, 2015 and List/Comp/14/2018-19 dated June 20, 2018, are enclosed as Annexure A. PFIZER LTD. - 500680 - Unaudited Financial Results For The Third Quarter And Nine Months Ended December 31, 2022.
Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit Herewith the unaudited financial results for the third quarter and nine months ended December 31, 2022. The said results were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 2.45 p.m. and concluded at 4.30 p.m. Also please find enclosed the Limited Review Report by our Auditors M/s. B S R & Co., LLP, in respect of the above results. Please take the above on record. PFIZER LTD. - 500680 - Board Meeting Outcome for Unaudited Financial Results For The Third Quarter And Nine Months Ended December 31, 2022.
Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the unaudited financial results for the third quarter and nine months ended December 31, 2022. The said results were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 2.45 p.m. and concluded at 4.30 p.m. Also please find enclosed the Limited Review Report by our Auditors M/s. B S R & Co., LLP, in respect of the above results. Please take the above on record.
HC directs firm to pay Rs 2 crore damages to Pfizer for contempt of court
The Delhi High Court has directed a firm to pay Rs 2 crore as damages to pharma giant Pfizer Inc for committing wilful" and "contumacious contempt of court by disobeying its order. The court said if the director of the firm, Triveni Interchem Pvt Ltd, fails to pay the amount in two weeks, he shall be taken into custody and detained in a civil prison for two weeks at Tihar jail here. The court, in an interim order, had restrained the firm from making, selling, distributing, advertising, exporting or importing or dealing with any product having compound Palbociclib' or any pharmaceutically acceptable salt as it would infringe the patent of plaintiff Pfizer. As the firm was found continuing to sell Palbociclib, the court held the defendants guilty of wilful disobedience of its order and committing contempt of court. In these circumstances, as the defendants were completely unwilling to acknowledge the fact that it was selling Palbociclib, the court was constrained to hold the defendan PFIZER LTD. - 500680 - Board Meeting Intimation for Board Meeting For Consideration And To Take On Record The Unaudited Financial Results For The Quarter Ended December 31, 2022.
PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2023 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, February 9, 2023, inter alia, to consider and take on record the Unaudited Financial Results of the Company for the quarter ended December 31, 2022. Pursuant to the 'Pfizer Limited - Code of Internal Procedures and Conduct to Regulate, Monitor and Report Trading by Insiders', the Trading Window of the Company was closed from Saturday, December 31, 2022, till 48 hours after the results are made public on February 9, 2023. We request you to kindly take the above on record. Pfizer predicts bigger-than-expected sales drop for two key products
Pfizer surprised Wall Street with a prediction for a bigger-than-expected sales drop this year for two key products: its COVID-19 vaccine and treatment. The drugmaker also released an earnings forecast that is below analyst expectations, sending shares lower before the opening bell Tuesday. Pfizer expects sales of both the vaccine Comirnaty and the treatment Paxlovid to tumble next year before starting to rebound. That drop was expected as the drugmaker shifts from supplying government contracts to sales on the commercial market in the United States. But Pfizer said Tuesday that it expects Comirnaty sales to tumble 64% to about $13.5 billion this year. It predicts a 58% drop for Paxlovid to about $8 billion. Wall Street expects more than $14 billion in sales from Comirnaty and another $10.5 billion from Paxlovid, according to FactSet. Overall, Pfizer predicts that adjusted earnings will range between $3.25 and $3.45 per share in the new year. Analysts forecast earnings of $4.34
US CDC looks at potential stroke risk from Pfizer bivalent COVID shot
US Food and Drug Administration officials said they had not detected a link between the shots and strokes in two other safety monitoring databases.
Biggest challenge during pandemic was negotiating politics: Pfizer
Protectionism as a result of fear meant the governments closed down borders, making it difficult to export vaccines, says Albert Bourla, Pfizer's chief executive officer